EMI1

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

EMI1 是 EGFR 三重突变体 EGFR ex19del/T790M/C797S 和 EGFR L858R/T790M/C797S 的有效抑制剂。EMI1 可用于与 EGFR 突变相关的耐药型非小细胞肺癌 (NSCLC) 的研究。

EMI1 is an EGFR ex19del/T790M/C797S and EGFR L858R/T790M/C797S inhibitor. EMI1 can be used for the research of mutant EGFR-associated, drug-resistant non-small-cell lung cancer (NSCLC).

EMI1 inhibits PC9 EGFR ex19del/T790M/C797S organoid growth with the EC50 of 131 nM.EMI1 (1 nM-10 μM) potently reduces the interaction of EGFR triple mutant with Shc1.EMI1 (1 nM-100μM) strongly inhibits the viability and increase the caspase 3/7 activity of PC9 EGFR ex19del/T790M/C797S triple-mutant cells than noncancerous human bronchial epithelial (HBE) cells..Cell Viability Assay Cell Line:PC9 EGFR ex19del/T790M/C797S and HBE bronchial epithelial lung EGFR-WT control cells. Concentration: 0.001, 0.01, 0.1, 1, 10, 100 μM Incubation Time:72 hours Result:Strongly inhibited the viability.

——

——

Angiogenesis

EGFR

EGFR

——

——

35773-42-3

334.37

C20H18N2O3

>98% (HPLC)

In Vitro:?DMSO 中的溶解度 : 25 mg/mL (74.77 mM; 超声助溶 (<60°C)

CCN(CC)C1=CC2=C(C=C1)C=C(C1=NC3=C(O1)C=CC=C3)C(=O)O2

——

(-20℃)

With Ice Pack

≥ 2 years